Filtered By:
Source: Stroke
Drug: Activase

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Intravenous Thrombolysis in Unknown-Onset Stroke Clinical Sciences
Conclusions—Our data suggest no excess risk of symptomatic intracerebral hemorrhage but increased mortality and reduced favorable outcome in patients with UKO stroke compared with patients treated within the approved time window.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Laura Dorado, Niaz Ahmed, Gotz Thomalla, Manuel Lozano, Branko Maloȷcic, Mushtaq Wani, Monica Millan, Ales Tomek, Antoni Davalos Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Drip 'n Ship Versus Mothership for Endovascular Treatment Brief Report
Conclusions—Drip ‘n Ship demonstrates that a PSC that is in close proximity to a CSC remains significant only when the PSC is able to achieve a door-to-needle time of ≤30 minutes when the CSC is also efficient.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Matthew S.W. Milne, Jessalyn K. Holodinsky, Michael D. Hill, Anders Nygren, Chao Qiu, Mayank Goyal, Noreen Kamal Tags: Quality and Outcomes, Ischemic Stroke Brief Reports Source Type: research

Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke Clinical Sciences
Conclusions—Intravenous thrombolytics provide benefit to stroke patients with computed tomographic angiography or magnetic resonance angiography evidence of arterial obstruction, but the sample was underpowered to demonstrate significant treatment benefit or harm among patients with apparently patent arteries.Clinical Trial Registration—URL: http://www.isrctn.com. Unique identifier: ISRCTN25765518.
Source: Stroke - January 22, 2017 Category: Neurology Authors: Grant Mair, Rudiger von Kummer, Alessandro Adami, Philip M. White, Matthew E. Adams, Bernard Yan, Andrew M. Demchuk, Andrew J. Farrall, Robin J. Sellar, Eleni Sakka, Jeb Palmer, David Perry, Richard I. Lindley, Peter A.G. Sandercock, Joanna M. Wardlaw Tags: Angiography, Meta Analysis, Ischemic Stroke Original Contributions Source Type: research

Uric Acid Therapy Prevents Early Ischemic Stroke Progression Brief Report
Conclusions—UA therapy may prevent EIW after acute stroke in thrombolysed patients. Optimal access of UA to its molecular targets through appropriate collaterals may modify the magnitude of the neuroprotective effect.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00860366.
Source: Stroke - October 23, 2016 Category: Neurology Authors: Amaro, S., Laredo, C., Renu, A., Llull, L., Rudilosso, S., Obach, V., Urra, X., Planas, A. M., Chamorro, A. Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Neuroprotectants Brief Reports Source Type: research

Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients Brief Reports
Conclusions— Intravenous tirofiban immediately after alteplase seems to be safe and potentially more effective when compared with alteplase alone for selected stroke patients. Clinical Trial Registration— URL: http://www.chictr.org.cn/. Unique identifier: ChiCTR-TRC-14004630.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Li, W., Lin, L., Zhang, M., Wu, Y., Liu, C., Li, X., Huang, S., Liang, C., Wang, Y., Chen, J., Feng, W. Tags: Pharmacology, Treatment, Ischemic Stroke Brief Reports Source Type: research

Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone Clinical Sciences
Conclusions— THERAPY did not achieve its primary end point in this underpowered sample. Directions of effect for all prespecified outcomes were both internally and externally consistent toward benefit. It is possible that an alternate method of thrombectomy, primary aspiration, will benefit selected patients harboring large vessel occlusions. Further study on this topic is indicated. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01429350.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Mocco, J., Zaidat, O. O., von Kummer, R., Yoo, A. J., Gupta, R., Lopes, D., Frei, D., Shownkeen, H., Budzik, R., Ajani, Z. A., Grossman, A., Altschul, D., McDougall, C., Blake, L., Fitzsimmons, B.-F., Yavagal, D., Terry, J., Farkas, J., Lee, S. K., Baxter Tags: Ischemic Stroke Clinical Sciences Source Type: research

Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials Clinical Sciences
Conclusions— Treatment with intravenous alteplase initiated within 4.5 hours of stroke onset increases the chance of achieving an improved level of function for all patients across the age spectrum, including the over 80s and across all severities of stroke studied (top versus bottom fifth means: 22 versus 4); the earlier that treatment is initiated, the greater the benefit.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Lees, K. R., Emberson, J., Blackwell, L., Bluhmki, E., Davis, S. M., Donnan, G. A., Grotta, J. C., Kaste, M., von Kummer, R., Lansberg, M. G., Lindley, R. I., Lyden, P., Murray, G. D., Sandercock, P. A. G., Toni, D., Toyoda, K., Wardlaw, J. M., Whiteley, Tags: Treatment, Cerebrovascular Disease/Stroke, Cerebrovascular Procedures, Ischemic Stroke Clinical Sciences Source Type: research

In-Transit Telemedicine Speeds Ischemic Stroke Treatment: Preliminary Results Brief Reports
Conclusions— Improvement in time to treat seems comparable with in-transit telestroke and mobile stroke transport units. The low cost/unit makes this approach scalable, potentially providing rapid management of more patients.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Belt, G. H., Felberg, R. A., Rubin, J., Halperin, J. J. Tags: Clinical Studies, Ischemic Stroke Brief Reports Source Type: research

Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis Basic Sciences
Conclusions— Our results provide the basis needed for the design of future preclinical studies on recanalization therapies using this model of thromboembolic stroke in mice. The power analysis reveals that a multicenter trial would require 123 animals per group instead of 40 for a single-center trial.
Source: Stroke - April 24, 2016 Category: Neurology Authors: Orset, C., Haelewyn, B., Allan, S. M., Ansar, S., Campos, F., Cho, T. H., Durand, A., El Amki, M., Fatar, M., Garcia-Yebenes, I., Gauberti, M., Grudzenski, S., Lizasoain, I., Lo, E., Macrez, R., Margaill, I., Maysami, S., Meairs, S., Nighoghossian, N., Or Tags: Animal Models of Human Disease, Ischemic Stroke Basic Sciences Source Type: research

Intra-Arterial Therapy and Post-Treatment Infarct Volumes: Insights From the ESCAPE Randomized Controlled Trial Clinical Sciences
Conclusions— These results support the primary results of the ESCAPE trial and show that the biological underpinning of the success of endovascular therapy is a reduction in infarct volume. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.
Source: Stroke - February 22, 2016 Category: Neurology Authors: Al-Ajlan, F. S., Goyal, M., Demchuk, A. M., Minhas, P., Sabiq, F., Assis, Z., Willinsky, R., Montanera, W. J., Rempel, J. L., Shuaib, A., Thornton, J., Williams, D., Roy, D., Poppe, A. Y., Jovin, T. G., Sapkota, B. L., Baxter, B. W., Krings, T., Silver, F Tags: Imaging, Quality and Outcomes, Ischemic Stroke Clinical Sciences Source Type: research

Safety and Efficacy of Solitaire Stent Thrombectomy: Individual Patient Data Meta-Analysis of Randomized Trials Clinical Sciences
Conclusions— Solitaire thrombectomy for large vessel ischemic stroke was safe and highly effective with substantially reduced disability. Benefits were consistent in all prespecified subgroups.
Source: Stroke - February 22, 2016 Category: Neurology Authors: Campbell, B. C. V., Hill, M. D., Rubiera, M., Menon, B. K., Demchuk, A., Donnan, G. A., Roy, D., Thornton, J., Dorado, L., Bonafe, A., Levy, E. I., Diener, H.-C., Hernandez-Perez, M., Pereira, V. M., Blasco, J., Quesada, H., Rempel, J., Jahan, R., Davis, Tags: Ischemic Stroke Clinical Sciences Source Type: research

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association AHA/ASA Scientific Statement
Purpose— To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of altepla...
Source: Stroke - January 25, 2016 Category: Neurology Authors: Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., Saposnik, G., Saver, J. L., Smith, E. E., on behalf of the American Heart Association Stro Tags: Statements and Guidelines AHA/ASA Scientific Statement Source Type: research

Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis Brief Reports
Conclusions— Clinicians are poor at approximating the weights of patients with stroke in the acute setting, especially when patients lie at the extremes of weight. Beds capable of weighing patients should be mandated in emergency rooms for patients with acute stroke.
Source: Stroke - December 28, 2015 Category: Neurology Authors: Barrow, T., Khan, M. S., Halse, O., Bentley, P., Sharma, P. Tags: Treatment Brief Reports Source Type: research

Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke Brief Reports
Conclusions— In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
Source: Stroke - November 23, 2015 Category: Neurology Authors: Huang, X., Moreton, F. C., Kalladka, D., Cheripelli, B. K., MacIsaac, R., Tait, R. C., Muir, K. W. Tags: Treatment, Ischemic Stroke, Thrombosis Brief Reports Source Type: research

Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event Clinical Sciences
Conclusions— Patients currently treated with alteplase, despite a history of previous stroke ≤3 months, do not seem to achieve worse outcome than those with first-ever stroke. Although careful patient selection was probably of major importance, our findings provide reassurance that this group of patients may safely benefit from thrombolysis and should not be arbitrarily excluded as a whole. Further studies are needed to identify the shortest safe time lapse from the previous event to treatment with alteplase.
Source: Stroke - October 26, 2015 Category: Neurology Authors: Karlinski, M., Kobayashi, A., Czlonkowska, A., Mikulik, R., Vaclavik, D., Brozman, M., Gdovinova, Z., Švigelj, V., Csiba, L., Fekete, K., Korv, J., Demarin, V., Bašic-Kes, V., Vilionskis, A., Jatuzis, D., Krespi, Y., Shamalov, N., Andonova, Tags: Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research